Document is current
Any future updates will be listed below
-
Authors
Truini, Andrea https://orcid.org/0000-0002-2630-7647
Bhaskar, Arun
Fornasari, Diego https://orcid.org/0000-0002-9668-3103
Bouhassira, Didier
Collins, Michael
Baron, Ralf https://orcid.org/0000-0002-9492-4698
Pickering, Gisele
-
Funding
Funding for this research was provided by:
Fundação Grünenthal
- License Information
-
More Information
Article History
Received: 30 January 2026
Accepted: 19 March 2026
First Online: 17 April 2026
Declarations
:
: Andrea Truini has received consultancy fees from Amgen, AbbVie, Exeltis, Grünenthal, Pharmaline, and Viatris. Diego Fornasari has received fees as consultant or congress speaker or member of advisory boards from Angelini, Alfasigma, Abiogen, Chiesi, Grünenthal, Molteni, Sandoz, SPA, Viatris, and Zambon. Ralf Baron has received grant/research support from: Europain (115007), DOLORisk (633491), IMI Paincare (777500), German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Frühdetektion von Schmerzchronifizierung (NoChro) (13GW0338C), German Research Network on Neuropathic Pain (01EM0903), Pfizer Pharma GmbH, Grünenthal GmbH, Mundipharma Research GmbH and Co. KG., Alnylam Pharmaceuticals Inc., Zambon GmbH, Sanofi Aventis GmbH, and Viatris; speaker fees from: Pfizer Pharma GmbH, Sanofi Aventis GmbH, Grünenthal GmbH, Mundipharma, Lilly GmbH, Desitin Arzneimittel GmbH, Teva GmbH, Bayer AG, MSD GmbH, Seqirus Australia Pty. Ltd., Novartis Pharma GmbH, TAD Pharma GmbH, Grünenthal SA Portugal, Grünen-thal Pharma AG Schweiz, Grünenthal B.V. Niederlande, Evapharma, Takeda Pharmaceuticals International AG Schweiz, Ology Medical Education Netherlands, Ever Pharma GmbH, Amicus Therapeutics GmbH, Novo Nordisk Pharma GmbH, Chiesi GmbH, Stada Mena DWC LLC Dubai, Hexal AG, Viatris, AstraZeneca GmbH, Sandoz, Aristo, Esanum, and Docflix GmbH; consultancy fees from: Pfizer Pharma GmbH, Sanofi Aventis GmbH, Grünenthal GmbH, Lilly, Novartis Pharma GmbH, Bristol-Myers Squibb, Biogenidec, AstraZeneca GmbH, Daiichi Sankyo, Glenmark Pharmaceuticals S.A., Seqirus Australia Pty. Ltd., Teva Pharmaceuticals Europe Niederlande, Teva GmbH, Genentech, Mundipharma International Ltd. UK, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene GmbH, Desitin Arzneimittel GmbH, Regeneron Pharmaceuticals Inc. USA, Theranexus DSV CEA Frankreich, Abbott Products Operations AG Schweiz, Bayer AG, Grünenthal Pharma AG Schweiz, Akcea Therapeutics Germany GmbH, Asahi Kasei Pharma Corporation, AbbVie Deutschland GmbH and Co. KG, Air Liquide Sante International Frankreich, Alnylam Germany GmbH, Lateral Pharma Pty Ltd., Hexal AG, Angelini, Janssen, SIMR Biotech Pty Ltd. Australien, Confo Therapeutics N.V. Belgium, Merz Pharmaceuticals GmbH, Neumentum Inc., F. Hoffmann-La Roche Ltd. Switzerland, AlgoTherapeutix SAS France, Nanobiotix SA France, AmacaThera Inc. Canada, Hoba Therapeutics, Heat2Move, Resano GmbH, Esteve Pharmaceuticals SA, Aristo, Viatris, and Vertanical GmbH. Gisele Pickering has received honoraria from Grünenthal, GSK, and Opella Healthcare. Arun Bhaskar has nothing to disclose. Didier Bouhassira has nothing to disclose. Michael Collins has nothing to disclose.
: The conduct of the study adhered to the ethical principles outlined in the Declaration of Helsinki (2013). This study did not require ethics committee approval as it was a noninterventional opinion-based Delphi process involving HCPs and patients, with no collection of sensitive or participant-identifiable data. All responses were anonymous. A statement of consent was included at the start of the survey, and completion of the survey constituted informed consent. All respondents received a nominal fee for completing the survey. This study was not prospectively registered.
